| Molecule | Cat. No. | Product Name | Species | Host | Structure | Purity | Activity | Size&Price |
|---|---|---|---|---|---|---|---|---|
| GDF-15 | HOT GD5-H5269 | Human GDF-15 / MIC-1 Protein, Fc Tag (MALS verified) | Human | HEK293 | ![]() | MALSSDS-PAGE | $395.00 100ug | |
| GDF-15 | HOTAvitag GD5-H81Q3 | Biotinylated Human GDF-15 / MIC-1 Protein, His,Avitag™ | Human | E. coli | ![]() | SDS-PAGE | $360.00 25ug | |
| GDF-15 | HOT GD5-C5148 | Cynomolgus GDF-15 / MIC-1 Protein, His Tag, low endotoxin | Cynomolgus | E. coli | ![]() | SDS-PAGE | $395.00 100ug | |
| GDF-15 | HOT GD5-H5149 | Human GDF-15 / MIC-1 Protein, His Tag, low Endotoxin | Human | E. coli | ![]() | SDS-PAGE | $435.00 100ug | |
| GDF-15 | Avitag GD5-H82F9 | Biotinylated Human GDF-15 / MIC-1 Protein, Avitag™, Fc Tag (MALS verified) | Human | HEK293 | ![]() | MALSSDS-PAGE | $360.00 25ug | |
| GDF-15 | Mouse GDF-15 / MIC-1 Protein, His Tag | Mouse | E. coli | ![]() | SDS-PAGE | $395.00 100ug |
| Project Name | Project Stage | Molecule Type | Molecule Source | Disease Area | Indication |
|---|---|---|---|---|---|
| GDF15 mAb - 01 | PCC | Monoclonal | Humanized Mouse | Metabolism | Solid tumor,Cancer cachexia |
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Visugromab | CTL-002 | Phase 3 Clinical | CatalYm GmbH | Cachexia; Carcinoma, Non-Small-Cell Lung; Solid tumours; Urinary Bladder Neoplasms | Details |
| Ponsegromab | PF-06946860 | Phase 3 Clinical | Pfizer Inc | Anorexia; Breast Neoplasms; Cachexia; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Colorectal Neoplasms; Fatigue; Feeding and Eating Disorders; Heart Failure; Ovarian Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms | Details |
| NGM-120 | NGM-120 | Phase 2 Clinical | NGM Biopharmaceuticals Inc | Anorexia; Cachexia; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Esophageal Neoplasms; Hyperemesis Gravidarum; Melanoma; Ovarian Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Urinary Bladder Neoplasms | Details |
| GDF15 agonist (Lilly) | Phase 1 Clinical | Eli Lilly And Company | Diabetes Mellitus | Details | |
| NN-9215 | Human-GDF15; MIC-1; NN-9215; LA-GDF15 | Phase 1 Clinical | Novo Nordisk A/S | Obesity | Details |
| GFS-202-A | GFS-202-A; GFS202A | Phase 1 Clinical | Genfleet Therapeutics (Shanghai) Co Ltd | Cachexia | Details |
| GB-18 | GB-18; GB18 | Phase 1 Clinical | Shandong Kexing Bio-Products Co Ltd | Cachexia | Details |
| CIN-109 | CIN-109; JNJ-9090 | Phase 1 Clinical | Janssen Sciences Ireland Unlimited Company | Obesity | Details |
| MBL-949 | MBL-949 | Phase 1 Clinical | Novartis Pharma Ag | Diabetes Mellitus; Obesity | Details |
| AV-380 | AV-380 | Phase 1 Clinical | Aveo Pharmaceuticals Inc | Cachexia | Details |